Assessing Variability in Vascular Response to Cocoa With Personal Devices: A Series of Double-Blind Randomized Crossover n-of-1 Trials

被引:7
作者
Bapir, Mariam [1 ]
Campagnolo, Paola [2 ]
Rodriguez-Mateos, Ana [3 ]
Skene, Simon S. [1 ]
Heiss, Christian [1 ,4 ]
机构
[1] Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Guildford, England
[2] Univ Surrey, Fac Hlth & Med Sci, Dept Biochem Sci, Guildford, England
[3] Kings Coll London, Fac Life Sci & Med, Sch Life Course & Populat Sci, Dept Nutr Sci, London, England
[4] Surrey & Sussex NHS Healthcare Trust, Vasc Dept, Redhill, England
来源
FRONTIERS IN NUTRITION | 2022年 / 9卷
基金
英国经济与社会研究理事会;
关键词
cocoa flavanols; n-of-1; blood pressure; pulse wave velocity; variability; flow-mediated dilation; FLAVANOL-RICH COCOA; CARDIOVASCULAR-DISEASE; ENDOTHELIAL FUNCTION; FLAVONOID INTAKE; ASSOCIATIONS; FLAVAN-3-OLS; AMLODIPINE; RISK;
D O I
10.3389/fnut.2022.886597
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Controlled clinical intervention studies have demonstrated that cocoa flavanols (CF) can decrease blood pressure and arterial stiffness in healthy humans, although a large variability in the effect size across trials has been reported. In this study, we evaluated the intra- and inter-individual variability of responses to CF in everyday life using a series of n-of-1 trials in healthy free-living individuals with normal blood pressure carrying personal devices. In total, eleven healthy young humans participated in a repeated crossover randomized controlled double-blind n-of-1 trial. On 8 consecutive days, each volunteer consumed on alternating days 6 CF capsules (862 mg CF) on 4 days and 6 matched placebo capsules (P, 0 mg CF/day) on another 4 days in one of the two randomized sequences (CF-P-CF-P-CF-P-CF-P or P-CF-P-CF-P-CF-P-CF). On each day, the capsules were taken at the same time in the morning with breakfast after baseline measurements. Each subject was provided with an upper arm blood pressure monitor and a finger clip that measures pulse wave velocity (PWV). Measurements of blood pressure, heart rate, and PWV were taken at least hourly over 12 h during the day by the participants. On the first 2 days, measurements were performed under supervision to provide training. The overall mixed model analysis showed that CF significantly decreased 12-h systolic blood pressure and PWV by -1.4 +/- 0.3 mmHg and -0.11 +/- 0.03 m/s, respectively. Peak effects were observed within the first 3 h (1.5 h SBP: -4.9 +/- 2.2 mmHg, PWV: -0.32 +/- 0.17 m/s) and again after 8 h post-ingestion. Large inter-individual variation in responses was found [intra-cluster correlation coefficients (ICC): 0.41, 0.41]. When analyzing single individuals' datasets, there was also considerable between-day variation in individual responses that varied greatly between subjects (ICC: 0-0.30, 0-0.22, 0-0.45). Effect sizes inversely correlated with baseline blood pressure values both between- and within-subjects. The data confirm that cocoa can decrease blood pressure and arterial stiffness in everyday life when elevated within the normal range. The large inter- and intra-individual variation in responses calls for more personalized nutritional intervention strategies.
引用
收藏
页数:10
相关论文
共 24 条
  • [21] Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
    Lodise, Thomas
    Colman, Sam
    Stein, Daniel S.
    Fitts, David
    Goldberg, Lisa
    Alexander, Elizabeth
    Scoble, Patrick J.
    Schranz, Jennifer
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (05):
  • [22] Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study
    Kumarathurai, Preman
    Anholm, Christian
    Fabricius-Bjerre, Andreas
    Nielsen, Olav W.
    Kristiansen, Ole
    Madsbad, Sten
    Haugaard, Steen B.
    Sajadieh, Ahmad
    JOURNAL OF HYPERTENSION, 2017, 35 (05) : 1070 - 1078
  • [23] A Phase 1, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety/Tolerability, Pharmacokinetic and Hemodynamic Response Following Single Ascending Subcutaneous Doses of PB1046 (Vasomera™) in Subjects with Essential Hypertension
    Free, Almena
    Brazg, Ronald
    Matson, Mark
    Smith, William
    Chuck, Leonard
    Georgopoulos, Lynne
    Malatesta, JoAnn
    Arnold, Susan
    Kramer, William
    Strange, Poul
    Shi, Leon
    Gwynne, John
    CIRCULATION, 2014, 130
  • [24] Evaluation of the Dose-Response Relationship of Aliskiren, a Direct Renin Inhibitor, in an 8-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study in Adult Patients With Stage 1 or 2 Essential Hypertension
    Puig, Juan G.
    Schunkert, Heribert
    Taylor, Addison A.
    Boye, Sam
    Jin, James
    Keefe, Deborah L.
    CLINICAL THERAPEUTICS, 2009, 31 (12) : 2839 - 2850